Denali Therapeutics (DNLI) Intangibles (2026)

Denali Therapeutics (DNLI) posted quarterly Intangibles of $36.0 million for Q1 2026.

Denali Therapeutics (DNLI) Intangibles (2026) Analysis & Trends

Denali Therapeutics (DNLI) has reported Intangibles for 1 consecutive years, with $36.0 million the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 412.80 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.31 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 266.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 63.28 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 60.96 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 93.49 Mn
10 Denali Therapeutics 3.90 Bn 3.90 Bn 3.51 Mn 35.25 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 35.25 Mn
Mar 31, 2026 36.00 Mn